Počet záznamů: 1
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
- 1.
SYSNO ASEP 0542897 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients Tvůrce(i) Raková, J. (CZ)
Truxová, I. (CZ)
Holicek, P. (CZ)
Šálek, C. (CZ)
Hensler, M. (CZ)
Kašíková, L. (CZ)
Pasulka, J. (CZ)
Holubová, M. (CZ)
Kovář, Marek (MBU-M) RID, ORCID
Lysák, D. (CZ)
Kline, J. P. (US)
Ráčil, Z. (CZ)
Galluzzi, L. (US)
Spíšek, R. (CZ)
Fučíková, J. (CZ)Číslo článku 1889822 Zdroj.dok. Oncoimmunology - ISSN 2162-402X
Roč. 10, č. 1 (2021)Poč.str. 13 s. Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova Co-inhibitory receptor ; innate lymphoid cells ; lag-3 ; tigit ; vista Vědní obor RIV EE - Mikrobiologie, virologie Obor OECD Microbiology Způsob publikování Open access Institucionální podpora MBU-M - RVO:61388971 UT WOS 000627790900001 EID SCOPUS 85102181179 DOI 10.1080/2162402X.2021.1889822 Anotace Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8(+) cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death 1 (PDCD1, best known as PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have limited clinical efficacy in patients with AML. Natural killer (NK) cells are central players in AML-targeting immune responses. However, little is known on the relationship between co-inhibitory receptors expressed by NK cells and the ability of the latter to control AML. Here, we show that hepatitis A virus cellular receptor 2 (HAVCR2, best known as TIM-3) is highly expressed by NK cells from AML patients, correlating with improved functional licensing and superior effector functions. Altogether, our data indicate that NK cell frequency as well as TIM-3 expression levels constitute prognostically relevant biomarkers of active immunity against AML. Pracoviště Mikrobiologický ústav Kontakt Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Rok sběru 2022 Elektronická adresa https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1889822
Počet záznamů: 1